Skip to main content
Full access
Letters to the Editor
Published Online: 1 June 2007

Dr. Wilens Replies

Publication: American Journal of Psychiatry
To The Editor: The authors comment on the validity of the case presented for meeting criteria for ADHD in light of substance abuse in general and marijuana abuse in particular. For teaching purposes, the case purposely left some areas vague, since it is illustrative of a typical presentation of ADHD in a young adult with marijuana use disorder. While in a perfect world, it would be nice to have adults present with an established childhood diagnosis with evidentiary documentation and completed full-structured interviews on their first-degree relatives, such data are not available in clinical practice. Epidemiological evidence clearly indicates that most adults with ADHD are neither diagnosed nor treated for their condition and that ADHD is not a trivial disorder with substantial impairment (1) . Hence, practitioners must evaluate the presence of symptoms and not make a formal diagnosis of ADHD in the parents of individuals being assessed indirectly for the disorder, which is often the case for substance use disorders. The idea that not all inattention is ADHD is obvious; however, if you can elicit a history of a longitudinal track of a cluster of attentional- and/or hyperactive/impulsive-based symptoms in childhood that are associated with impairment and exist at times when there is no substance abuse, a multiplicity of studies have demonstrated the validity of the retrospective diagnosis of ADHD in adults (2, 3), even in the presence of substance use disorders (4) . In the illustrative case that I presented, the ADHD symptoms can be tracked well into junior high school—a time when neither marijuana nor other psychiatric comorbidity was present—establishing a long history of ADHD symptoms and associated dysfunction (4) . The authors’ single-survey study of stimulant abusers does not settle the issue of whether concurrent marijuana use is the causative agent in all attentional-based dysfunction and all psychostimulant abuse. For instance, it has been reported that approximately 20% of adults with substance use disorders and 40% of cannabis abusing adolescents have an ADHD diagnosis after detoxification from marijuana (5, 6) (www. CSAT.gov). The authors lack data to support their contention that a diagnosis of ADHD can only be made with confidence after prolonged abstinence from nonmedical drug use. Unlike other comorbid disorders that are difficult to disentangle from substance use disorders, ADHD, by definition, predates substance use (onset ≤7 years old) and is a chronic disorder; there are no “attacks” of ADHD. Further, adults with ADHD who have been diagnosed with past and current substance use disorders compared with those diagnosed with no substance use have been shown to have similar characteristics, such as a family history of ADHD, neuropsychological disturbance, and functional impairments associated with ADHD symptoms (4) . Moreover, inspection of treatment studies of substance use disorders and ADHD shows a stable persistence in the symptoms of ADHD independent of the fluctuation of substance use throughout the trial (710) .
In terms of the treatment of substance use disorders, while abstinence is of course preferred, a number of studies that the authors do not mention show that ADHD is not benign when comorbid with substance use. The idea that only absolute abstinence is acceptable prior to initiating other treatment is ideologically based and does not appreciate that ADHD predicts earlier-onset substance use, more severe substance use, a longer course and less remission from substance use, and lower retention rates in the treatment of substance use (1114) . A number of innovative initiatives in this area that have led to newer guideline recommendations to treat ADHD in substance use disorders, after remission or stabilization of the substance use, have been established (14, 15) . This practice of treating ADHD in context with “stabilized” substance use has been recently shown to have a positive impact on improving the outcomes of substance use disorders (10) and is being evaluated currently in a large multisite National Institute on Drug Abuse study of adolescents with ADHD and substance use disorders. In this regard, there are a number of new options that could be used to accomplish these goals at different stages of substance use recovery, including effective nonstimulants.

Footnote

Dr. Wilens’s disclosure accompanies his original article.

References

1.
Kessler RC, Adler L, Barkley R, Biederman J, Conners CK, Demler O, Faraone SV, Greenhill LL, Howes MJ, Secnik K, Spencer T, Ustun TB, Walters EE, Zaslavsky AM: The prevalence and correlates of adult ADHD in the United States: results from the National Comorbidity Survey Replication. Am J Psychiatry 2006; 163:716–723
2.
Murphy P, Schachar R: Use of self-ratings in the assessment of symptoms of attention deficit hyperactivity disorder in adults. Am J Psychiatry 2000; 157:1156–1159
3.
Spencer T, Biederman J, Wilens TE, Faraone SV, Li T: Is attention deficit hyperactivity disorder in adults a valid diagnosis? Harv Rev Psychiatry 1994; 1:326–335
4.
Faraone SV, Wilens TE, Petty C, Antshel K, Spencer T, Biederman J: Substance use among ADHD adults: implications of late onset and subthreshold diagnoses. Am J Addict 2007; 16:24–34
5.
Schubiner H, Tzelepis A, Milberger S, Lockhart N, Kruger M, Kelley BJ, Schoener EP: Prevalence of attention-deficit/hyperactivity disorder and conduct disorder among substance abusers. J Clin Psychiatry 2000; 61:244–251
6.
Levin FR, Evans S, Kleber HD: Prevalence of adult attention-deficit/hyperactivity disorder among cocaine abusers seeking treatment. Drug Alcohol Depend 1998; 52:15–25
7.
Prince J, Wilens T, Waxmonsky J, Hammerness P, Monuteaux M, Goldman S, Brown S, Van Patten S, Gonzalez-Heydrich J, Spencer T, Doyle R, Biederman J: An open study of sustained-release bupropion in adults with ADHD and substance use disorders, in Scientific Proceedings of the American Psychiatric Association. Washington, DC, American Psychiatric Association, 2002, p NR 222
8.
Levin FR, Evans SM, Brooks DJ, Kalbag AS, Garawi F, Nunes EV: Treatment of methadone-maintained patients with adult ADHD: double-blind comparison of methylphenidate, bupropion and placebo. Drug Alcohol Depend 2006; 81:137–148
9.
Schubiner H, Saules KK, Arfken CL, Johanson CE, Schuster CR, Lockhart N, Edwards A, Donlin J, Pihlgren E: Double-blind placebo-controlled trial of methylphenidate in the treatment of adult ADHD patients with comorbid cocaine dependence. Exp Clin Psychopharmacol 2002; 10:286–294
10.
Brady KT, Wilens TE, Adler LA, Weiss MD, Ramsey JL, Michelson D, Ahrbecker L, Moore RJ, Renard D, Levine LR: Atomoxetine treatment of adults with ADHD and comorbid alcohol abuse disorder, in American College of Neuropsychopharmacology 45th Annual Meeting. Hollywood, Fla, American College of Neuropsychopharmacology, 2006
11.
Carroll KM, Rounsaville BJ: History and significance of childhood attention deficit disorder in treatment-seeking cocaine abusers. Compr Psychiatry 1993; 34:75–82
12.
Wilens TE, Biederman J, Mick E, Faraone SV, Spencer T: Attention deficit hyperactivity disorder (ADHD) is associated with early onset substance use disorders. J Nerv Ment Dis 1997; 185:475–482
13.
Wilens T, Biederman J, Mick E: Does ADHD affect the course of substance abuse?: findings from a sample of adults with and without ADHD. Am J Addict 1998; 7:156–163
14.
Wilson JJ, Levin FR: Attention-deficit/hyperactivity disorder and early-onset substance use disorders. J Child Adolesc Psychopharmacol 2005; 15:751–763
15.
Riggs PD: Clinical approach to treatment of ADHD in adolescents with substance use disorders and conduct disorder. J Am Acad Child Adolesc Psychiatry 1998; 37:331–332

Information & Authors

Information

Published In

Go to American Journal of Psychiatry
Go to American Journal of Psychiatry
American Journal of Psychiatry
Pages: 973 - 974
PubMed: 17541060

History

Published online: 1 June 2007
Published in print: June, 2007

Authors

Affiliations

TIMOTHY E. WILENS, M.D.

Metrics & Citations

Metrics

Citations

Export Citations

If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Simply select your manager software from the list below and click Download.

For more information or tips please see 'Downloading to a citation manager' in the Help menu.

Format
Citation style
Style
Copy to clipboard

There are no citations for this item

View Options

View options

PDF/ePub

View PDF/ePub

Get Access

Login options

Already a subscriber? Access your subscription through your login credentials or your institution for full access to this article.

Personal login Institutional Login Open Athens login
Purchase Options

Purchase this article to access the full text.

PPV Articles - American Journal of Psychiatry

PPV Articles - American Journal of Psychiatry

Not a subscriber?

Subscribe Now / Learn More

PsychiatryOnline subscription options offer access to the DSM-5-TR® library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.

Need more help? PsychiatryOnline Customer Service may be reached by emailing [email protected] or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).

Media

Figures

Other

Tables

Share

Share

Share article link

Share